ACRV | tickerfilter.com

Fundamental analysis

26%

Profitability 0%

Dept financing 10%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-9.93%

1 Month

-74.29%

3 Months

-75.14%

6 Months

-80.54%

1 Year

-85.86%

2 Year

-85.68%

Key data

Stock price

$1.36

P/E Ratio

0.00

DAY RANGE

$1.32 - $1.70

EPS

-$2.38

52 WEEK RANGE

$1.32 - $11.51

52 WEEK CHANGE

-$86.91

MARKET CAP

125.727 M

YIELD

N/A

SHARES OUTSTANDING

30.972 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

0.94

PUBLIC FLOAT

AVERAGE 10 VOLUME

$298,504

AVERAGE 30 VOLUME

$238,142

Company detail

CEO: Peter Blume-Jensen
Region: US
Website: acrivon.com
Employees: 0
IPO year: 2022

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. We were incorporated under the laws of the State of Delaware in March 2018. Our principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts.

ACRV - Acrivon Therapeutics, Inc.